Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on Wall Street. Shares of EMBC remained unmoved at $14.64 apiece in pre-market trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $26.4 million. That equals 45¢ per share on sales of $264 million for the three […]
MassDevice Earnings Roundup
Vivani to initiate study of semaglutide implant in 2026
Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over extended periods of time. Vivani aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug release profiles. It can also deliver large hydrophilic […]
Tandem stock rises after hours on Q3 beats, record sales
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of TNDM rose nearly 20% to $15.89 apiece in post-market trading today. The San Diego-based automated insulin delivery technology developer reported losses of $21.2 million. That equals 31¢ per share on sales […]
Insulet increases guidance again on Q3 beats, 30% sales uptick
Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the consensus forecast. Shares of PODD ticked up 2.4% to $322 apiece in pre-market trading today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $87.6 million. That equals $1.24 per share on sales of $706.3 million […]
Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
Senseonics (NYSE:SENS) shares ticked up after hours today on third-quarter results that beat the consensus sales forecast. Shares of SENS rose 2.1% to $6.87 apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $19.5 million. That equals 43¢ per share on sales of $8.1 million for […]
Dexcom leadership addresses G7 issue claims, hopes for expanded CGM coverage
Amid some scrutiny over its latest-generation G7 continuous glucose monitor (CGM), Dexcom (Nasdaq:DXCM) officials addressed claims on the company’s latest earnings call. A recent class action lawsuit brought G7 into the spotlight, demanding a jury trial for claims that Dexcom’s representations for G7 were false, misleading, and deceptive to consumers. The lawsuit says G7 places […]
Dexcom stock is down after hours despite Q3 beats, raised sales guidance
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of DXCM fell more than 8% to $62.69 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $283.8 million. That equals 70¢ per share on sales […]
Beta Bionics stock rises on Q3 beats, raised full-year guidance, advances iLet offerings
Beta Bionics (Nasdaq:BBNX) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of BBNX rose around 20% to $29 apiece in post-market trading today. The Irvine, California-based automated insulin delivery device maker reported losses of $14 million. That equals 33¢ per share on sales of […]
Abbott CEO expects continued growth in Diabetes Care with Libre 3, dual sensor
Abbott (NYSE:ABT) continues to get a boost in its Medical Devices business from its Diabetes Care unit’s portfolio of continuous glucose monitors (CGMs). In the company’s third-quarter earnings report released today, Abbott — one of the largest medtech companies in the world — fell shy of Wall Street’s sales expectations, but still reported more than 15% […]
Senseonics posts strong preliminary Q3 sales, reverse stock split
Senseonics (NYSE:SENS) today announced preliminary revenues for the third quarter and plans to conduct a reverse stock split. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker expects approximately $8.1 million in revenue for the third quarter of 2025. That marks a 91% uptick from the third quarter of 2024. The company attributed its growth […]
